Compare BLND & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLND | NGNE |
|---|---|---|
| Founded | 2012 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 365.1M | 327.8M |
| IPO Year | 2021 | 2014 |
| Metric | BLND | NGNE |
|---|---|---|
| Price | $1.56 | $28.75 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | $4.13 | ★ $63.57 |
| AVG Volume (30 Days) | ★ 2.8M | 145.8K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 58.33 | 0.93 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $123,585,000.00 | N/A |
| Revenue This Year | $12.62 | N/A |
| Revenue Next Year | $14.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.33 | $12.97 |
| 52 Week High | $4.49 | $37.27 |
| Indicator | BLND | NGNE |
|---|---|---|
| Relative Strength Index (RSI) | 49.95 | 66.87 |
| Support Level | $1.56 | $28.37 |
| Resistance Level | $1.69 | $29.05 |
| Average True Range (ATR) | 0.10 | 1.84 |
| MACD | 0.01 | 0.10 |
| Stochastic Oscillator | 60.66 | 91.52 |
Blend Labs Inc is a cloud-based platform software platform that powers the digital interface between financial services firms and consumers. It supports and simplifies applications for mortgages, consumer loans, and deposit accounts. Its operating segment is Blend Platform segment which comprises a suite of products that power the entire origination process from back-end workflows to consumer experience. The key revenue for the company is generated from the Blend Platform segment. Company has it's assets in united states, India and Mexico regions.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.